Novartis Kisqali hits endpoints in Phase III breast cancer trial

Novartis’ Kisqali hits endpoints in Phase III breast cancer trial

09:14 EDT 3 Jun 2019 | PharmaTimes

Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer.

Original Article: Novartis’ Kisqali hits endpoints in Phase III breast cancer trial

More From BioPortfolio on "Novartis’ Kisqali hits endpoints in Phase III breast cancer trial"